Protocol for high-throughput screening of ACE2 enzymatic activators to treat COVID-19-induced metabolic complications.
STAR Protoc
; 3(3): 101641, 2022 09 16.
Article
in English
| MEDLINE | ID: covidwho-2036622
ABSTRACT
Drug repositioning represents a cost- and time-efficient strategy for drug development. Here, we present a workflow of in silico screening of ACE2 enzymatic activators to treat COVID-19-induced metabolic complications. By using structure-based virtual screening and signature-based off-target effect identification via the Connectivity Map database, we provide a ranked list of the repositioning candidates as potential ACE2 enzymatic activators to ameliorate COVID-19-induced metabolic complications. The workflow can also be applied to other diseases with ACE2 as a potential target. For complete details on the use and execution of this protocol, please refer to Li et al. (2022).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Limits:
Humans
Language:
English
Journal:
STAR Protoc
Year:
2022
Document Type:
Article
Affiliation country:
J.xpro.2022.101641
Similar
MEDLINE
...
LILACS
LIS